The EPISODE trial of psychedelic-assisted therapy for ‘treatment-resistant depression’ finds only modest effects, with a few clear responders, but lingering methodological questions.
[read the full story...]
What happens when talking therapies or antidepressants don’t work? This new RCT tested whether mindfulness-based cognitive therapy (MBCT), delivered via Zoom, could help people with hard-to-treat depression, and whether it’s worth the cost. The results will interest NHS decision-makers.
[read the full story...]
Can ketamine help people with treatment-resistant depression, regardless of childhood trauma history? This new study suggests that trauma load and severity may not influence treatment outcomes.
[read the full story...]
A big new study suggests that certain genetic traits—like insomnia risk and neuroticism—may make depression harder to treat, while protective traits include education and cognitive ability.
[read the full story...]
Experts from across clinical trials, psychotherapy and regulation have been reflecting on the big challenges facing the field of psychedelics and mental health, following a late 2024 webinar hosted by IAMHRF. This new commentary explores where psychedelic mental health treatments might be heading and what needs to happen next.
[read the full story...]
Kirsten Lawson and Douglas Badenoch review the new randomised controlled trial by Cleare et al, published today in The Lancet Psychiatry, directly comparing the clinical and cost effectiveness of lithium and quetiapine as augmentation treatments for patients with ‘treatment resistant depression’.
[read the full story...]
Kirsten Lawson summarises a new ‘state of the art review’ in the BMJ which focuses on novel and emerging pharmacotherapy and neuromodulation for people with ‘treatment resistant depression’.
[read the full story...]
Amelia Talbot summarises a qualitative meta-synthesis exploring people’s experiences of living with ‘treatment-resistant’ depression.
[read the full story...]
In her debut blog, Ella Tuominen considers the Tavistock Adult Depression Study (TADS), which evaluated the cost-effectiveness of long-term psychoanalytic psychotherapy for treatment resistant depression compared to treatment as usual.
[read the full story...]
In this blog, UCL MSc students consider an RCT published in the New England Journal of Medicine, which suggests that psilocybin-assisted psychotherapy may help reduce depression in people with severe and enduring illness, but side effects are common and more research is needed to look into longer term effects.
[read the full story...]
